Q1 2021

Filed May 11, 2021 · 10-Q · 41 days after period end · 0001564590-21-026548

Q1 2021 · 10-Q

Revenue

$379.00K

±0.0% vs Q1 2020

Net Income

-$27.72M

N/M vs Q1 2020

EPS Diluted

-$0.54

N/M vs Q1 2020

Operating Income-$27,163,000N/M

Operating Cash Flow

Same quarter

Metric	Q1 2021	Q1 2020	Q1 2019	Q1 2018
Revenue	$379.00K	$379.00K	$379.00K	$379.00K
Net Income	-$27.72M	-$15.24M	-$14.30M	-$19.40M
EPS Diluted	-$0.54	-$0.56	-$0.53	$0.79

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR